PreprintCited by 51Protein Degradation and InhibitorsComputational Drug Discovery MethodsMachine Learning in Bioinformatics

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation

Open access

Preprint — published as 10.1016/j.gpb.2022.11.008 · Paper page

Abstract

Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell’s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed “degradability”, is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing degradability. We therefore developed a machine learning model, MAPD (Model-based Analysis of Protein Degradability), to predict degradability from protein features that encompass post-translational modifications, protein stability, protein expression and protein-protein interactions. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds (auPRC=0.759) and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins, including 278 cancer genes, that may be tractable to TPD drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.09.27.462040

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 109

  1. 10.1146/annurev.genet.30.1.405 · DOI
  2. 10.1152/physrev.00027.2001 · DOI
  3. 10.1016/S0092-8674(03)01074-2 · DOI
  4. 10.1016/S0092-8674(00)80929-0 · DOI
  5. 10.1073/pnas.141230798 · DOI · Paper page
  6. 2008, Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorganic & Medicinal Chemistry Letters, 18, 5904, 10.1016/j.bmcl.2008.07.114 · DOI · Paper page
  7. 10.1073/pnas.89.4.1249 · DOI
  8. 2017, Small-Molecule Modulation of Protein Homeostasis, Chemical Reviews, 117, 11269, 10.1021/acs.chemrev.7b00077 · DOI
  9. 2020, Prospecting for molecular glues, Nature chemical biology, 16, 1157, 10.1038/s41589-020-0620-z · DOI · Paper page
  10. 10.1016/j.cell.2019.11.031 · DOI · Paper page
  11. 2019, PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future, Drug Discovery Today: Technologies, 31, 15, 10.1016/j.ddtec.2019.01.002 · DOI
  12. 10.1016/j.chembiol.2015.05.009 · DOI · Paper page
  13. 10.1126/science.aab1433 · DOI · Paper page
  14. 10.1038/nature16979 · DOI · Paper page
  15. 10.1038/nchembio.2329 · DOI · Paper page
  16. 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nature Chemical Biology, 14, 706, 10.1038/s41589-018-0055-y · DOI · Paper page
  17. 2018, The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study, Cell Chem Biol, 25, 67, 10.1016/j.chembiol.2017.09.009 · DOI · Paper page
  18. 2018, Targeted protein degradation and the enzymology of degraders, Curr. Opin. Chem. Biol, 44, 47, 10.1016/j.cbpa.2018.05.004 · DOI · Paper page
  19. 10.1016/j.chembiol.2021.04.011 · DOI
  20. 10.1038/s41573-021-00199-0 · DOI · Paper page
  21. 10.1016/j.pharmthera.2012.07.004 · DOI · Paper page
  22. 10.1016/S1286-4579(02)01645-3 · DOI
  23. 10.1073/pnas.91.9.4082 · DOI · Paper page
  24. 10.1097/00001622-200011000-00009 · DOI
  25. 10.1126/science.1177319 · DOI · Paper page
  26. 10.1126/science.1244851 · DOI · Paper page
  27. 10.1126/science.1244917 · DOI · Paper page
  28. 2014, Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nature Structural & Molecular Biology, 21, 803, 10.1038/nsmb.2874 · DOI · Paper page
  29. 2019, Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera, Sci. Rep, 9, 19654, 10.1038/s41598-019-56177-5 · DOI
  30. 2020, Novel immunomodulatory drugs and neo-substrates, Biomark Res, 8, 2, 10.1186/s40364-020-0182-y · DOI · Paper page
  31. 10.1126/science.1249543 · DOI
  32. Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, (2018). · DOI · Paper page
  33. 10.1038/nature13527 · DOI · Paper page
  34. 2021, PROTAC-DB: an online database of PROTACs, Nucleic Acids Res, 49, D1381, 10.1093/nar/gkaa807 · DOI · Paper page
  35. 10.1073/pnas.1521738113 · DOI · Paper page
  36. 2020, First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI), Journal of Clinical Oncology, 38, 3500, 10.1200/JCO.2020.38.15_suppl.3500 · DOI · Paper page
  37. 2019, ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer, Journal of Clinical Oncology, 37, 259, 10.1200/JCO.2019.37.7_suppl.259 · DOI
  38. 10.1158/1538-7445.sabcs18-p5-04-18 · DOI
  39. He, Y. et al. DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology vol. 13 (2020). · DOI · Paper page
  40. 2020, Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma, J. Med. Chem, 63, 6648, 10.1021/acs.jmedchem.9b01928 · DOI · Paper page
  41. 10.31525/ct1-nct03930953 · DOI
  42. 2021, Targeted protein degraders crowd into the clinic, Nat. Rev. Drug Discov, 20, 247, 10.1038/d41573-021-00052-4 · DOI · Paper page
  43. 2021, Reimagining Druggability Using Chemoproteomic Platforms, Acc. Chem. Res, 54, 1801, 10.1021/acs.accounts.1c00065 · DOI · Paper page
  44. 2020, Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development, Cell, 183, 1714, 10.1016/j.cell.2020.10.038 · DOI · Paper page
  45. 2018, A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader, Cell Chem Biol, 25, 88, 10.1016/j.chembiol.2017.10.005 · DOI · Paper page
  46. 2018, Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead, Cell Chem Biol, 25, 78, 10.1016/j.chembiol.2017.09.010 · DOI · Paper page
  47. 10.1016/j.chembiol.2021.07.002 · DOI
  48. 10.1101/451948 · DOI
  49. 2019, In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application, J. Chem. Inf. Model, 59, 1634, 10.1021/acs.jcim.8b00872 · DOI · Paper page
  50. 2020, PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes, J. Chem. Inf. Model, 60, 4894, 10.1021/acs.jcim.0c00589 · DOI · Paper page
  51. 2021, Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta, J. Chem. Inf. Model, 61, 1368, 10.1021/acs.jcim.0c01451 · DOI · Paper page
  52. 10.1101/2020.07.10.197186 · DOI
  53. 10.1038/s41589-019-0294-6 · DOI · Paper page
  54. 10.1038/s41467-018-08027-7 · DOI · Paper page
  55. 10.1681/ASN.2006010083 · DOI · Paper page
  56. 2020, Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition, Clin. Proteomics, 17, 2, 10.1186/s12014-020-9265-x · DOI
  57. 10.1038/35008096 · DOI
  58. Mészáros, B. , Kumar, M. , Gibson, T. J. , Uyar, B. & Dosztányi, Z. Degrons in cancer. Sci. Signal. 10, (2017). · DOI
  59. 2020, Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1, Eur. J. Med. Chem, 199, 112377, 10.1016/j.ejmech.2020.112377 · DOI
  60. 2018, Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6, ACS Chem. Biol, 13, 3131, 10.1021/acschembio.8b00698 · DOI · Paper page
  61. 10.1093/nar/gku1267 · DOI · Paper page
  62. 10.1080/02648725.2013.801232 · DOI
  63. Liu, H. & Motoda, H . Computational Methods of Feature Selection. (CRC Press, 2007). · DOI
  64. 10.1093/nar/gkx1037 · DOI · Paper page
  65. 10.1093/nar/gky1075 · DOI · Paper page
  66. 2021, Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries, Nat. Biotechnol, 39, 630, 10.1038/s41587-020-00778-3 · DOI · Paper page
  67. 10.1038/s41573-021-00245-x · DOI · Paper page
  68. 10.1093/nar/gkz972 · DOI · Paper page
  69. 2019, AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors, Nucleic Acids Res, 47, D33, 10.1093/nar/gky822 · DOI
  70. 10.1016/j.cell.2018.01.029 · DOI · Paper page
  71. 2020, Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment, Neoplasia, 22, 111, 10.1016/j.neo.2019.12.003 · DOI
  72. Kim, G.-Y. et al. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs. Molecules 26, (2021). · DOI
  73. 2019, Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands, J. Med. Chem, 62, 11218, 10.1021/acs.jmedchem.9b01393 · DOI
  74. 10.1021/acs.jmedchem.1c00847 · DOI
  75. 2021, Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer, J. Clin. Oncol, 39, 1360, 10.1200/JCO.20.02272 · DOI
  76. 10.1158/1535-7163.MCT-20-0390 · DOI · Paper page
  77. 2020, GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models, Breast Cancer Res. Treat, 180, 359, 10.1007/s10549-020-05558-w · DOI
  78. 10.1158/1078-0432.CCR-16-2561 · DOI
  79. 10.1016/j.chembiol.2012.04.008 · DOI
  80. 2019, A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation, Cell Chem Biol, 26, 1544, 10.1016/j.chembiol.2019.08.009 · DOI
  81. 10.1002/bip.360221211 · DOI · Paper page
  82. 10.1016/j.cell.2011.10.035 · DOI · Paper page
  83. 10.1016/j.cell.2011.09.019 · DOI
  84. 10.1126/science.1160462 · DOI
  85. 10.1126/science.1160489 · DOI · Paper page
  86. 10.1038/s41467-018-03106-1 · DOI
  87. 10.1074/mcp.RA118.000583 · DOI
  88. Szklarczyk, D. , et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research vol. 47 D607–D613 (2019). · DOI · Paper page
  89. 10.1093/nar/gky973 · DOI · Paper page
  90. 10.1016/j.cell.2019.12.023 · DOI · Paper page
  91. 10.1016/j.cell.2020.08.036 · DOI · Paper page
  92. 10.1016/j.molcel.2017.06.004 · DOI · Paper page
  93. 10.1093/nar/gku982 · DOI
  94. 10.1093/bioinformatics/btw313 · DOI
  95. 10.1201/9780429341830-30 · DOI
  96. 2018, Pre-processing and Modelling using Caret Package in R, International Journal of Computer Applications, 181, 39, 10.5120/ijca2018917530 · DOI
  97. Robin, X. et al. pROC: an open-source package for R and S to analyze and compare ROC curves. BMC Bioinformatics vol. 12 (2011). · DOI · Paper page
  98. 10.1093/bioinformatics/btv153 · DOI
  99. 10.1186/s12859-016-1433-7 · DOI
  100. 10.1016/j.molcel.2020.07.001 · DOI
  101. 2021, RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences, Nucleic Acids Res, 49, D437, 10.1093/nar/gkaa1038 · DOI · Paper page
  102. 10.1093/nar/gky427 · DOI
  103. 10.1093/nar/gkt1144 · DOI
  104. 10.1158/0008-5472.CAN-15-3190 · DOI
  105. 10.1093/bioinformatics/btl461 · DOI
  106. 10.1038/nsb1097-796 · DOI
  107. 10.1038/s41592-020-0848-2 · DOI · Paper page
  108. 10.1093/bioinformatics/bty355 · DOI · Paper page
  109. 10.1074/jbc.M102060200 · DOI

Metadata

Authors
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Zhang, B., Zeng, Z., Zhang, Y., Li, D., Fischer, E. S., Tokheim, C., & Liu, X. S.
Affiliations
  • Harvard University (US)
  • Sichuan University (CN)
Corresponding author
  • Fischer, Eric S.
  • Tokheim, Collin
  • Liu, X. Shirley
Venue
Genomics Proteomics & Bioinformatics
Publisher
openRxiv
Published
2021-09-29
Volume
20
Issue
5
Pages
882-898
ISSN
1672-0229 (ISSN-L)
OpenAlex
W4310760182
Cited by
51
References
2
Citations by year
2026: 15 · 2025: 10 · 2024: 16 · 2023: 4 · 2022: 6
FWCI
2.92
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Genomics Proteomics & Bioinformatics (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Cancer Research Institute
  • Breast Cancer Research Foundation (BCRF-19-100)
  • Damon Runyon Cancer Research Foundation (DRQ-04-20)
  • Astellas Pharma US
  • Harvard Medical School
  • Dana-Farber Cancer Institute
  • Deutsches Krebsforschungszentrum (CRI 3442)
  • Mark Foundation For Cancer Research (19-001-ELA)
  • Istituto Superiore di Sanità
  • National Institutes of Health
  • National Cancer Institute (R01CA214608, R01CA218278)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
Keywords
targeted protein degradation, kinases, undruggable proteins, cancer genes
MeSH terms
Machine Learning, Lysine, Proteome, Ubiquitination, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review